Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: BioDelivery falls on Phase III miss

    BioDelivery Sciences International Inc. (NASDAQ:BDSI) shed $3.38 (24%) to $10.51 on Monday after its clonidine topical gel (ARC-4558) missed the primary endpoint in a Phase III trial to treat painful diabetic neuropathy…

    Published on 3/30/2015
  • CLINICAL NEWS: Chi-Med's fruquintinib meets in mCRC Phase II

    Hutchison China MediTech Ltd. (LSE:HCM) said fruquintinib (HMPL-013) met the primary endpoint of progression-free survival (PFS) in a Chinese Phase II study to treat metastatic colorectal cancer (mCRC). Chi-Med said its…

    Published on 3/30/2015
  • CLINICAL NEWS: Genfit sinks on Phase II NASH data

    Genfit S.A. (Euronext:GNFT) plunged EUR 22.54 (44%) to a six-month low of EUR 28.31 on Friday after its GFT505 missed the primary endpoint in the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH)…

    Published on 3/27/2015
  • CLINICAL NEWS: Northwest gains on GBM survival data

    Northwest Biotherapeutics Inc. (NASDAQ:NWBO) reported data from glioblastoma multiforme (GBM) patients who were ineligible for enrollment in the company's ongoing Phase III trial of DCVax-Brain (DCVax-L), and instead …

    Published on 3/27/2015
  • CLINICAL NEWS: Conatus' emricasan meets Phase II endpoint

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) jumped $1 (17%) to $6.76 on Thursday after it said pan-caspase inhibitor emricasan met the primary endpoint of a Phase II trial to treat non-alcoholic fatty liver disease (…

    Published on 3/26/2015
  • CLINICAL NEWS: Genfit reports Phase II NASH data

    Genfit S.A. (Euronext:GNFT) said GFT505 missed the primary endpoint of the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH) according to the study's initial design. GFT505 met the endpoint after …

    Published on 3/26/2015
  • CLINICAL NEWS: VBL gains on Phase II GBM data

    VBL Therapeutics Ltd. (NASDAQ:VBLT) gained $1.63 (29%) to $7.22 on Wednesday after VB-111 met the primary endpoint of improving overall survival (OS) in a Phase II trial to treat recurrent glioblastoma multiforme (GBM).…

    Published on 3/25/2015
  • CLINICAL NEWS: NGM to chart new course for lead compound

    NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) said its NGM282 met the primary endpoint in a Phase II trial to treat primary biliary cirrhosis (PBC), but now plans to study the compound to treat other Orphan …

    Published on 3/24/2015
  • CLINICAL NEWS: Silence golden on pancreatic cancer data

    Silence Therapeutics plc (LSE:SLN) climbed 50.5p (21%) to 288p after preliminary Phase IIa data suggested the biotech's Atu027 had a dose-dependent effect in advanced pancreatic cancer patients. The study included 23 …

    Published on 3/23/2015
  • CLINICAL NEWS: Vertex reports Phase II CF combo data

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shed $5.21 to $125.79 on Monday after reporting the first 12-week data for VX-661 plus Kalydeco ivacaftor to treat cystic fibrosis in patients with two copies of the delta F508 …

    Published on 3/23/2015
  • CLINICAL NEWS: Prothena soars on Phase I Parkinson's data

    Prothena Corp. plc (NASDAQ:PRTA) rose $9.43 (32%) to $38.66 on Friday after it said Parkinson's disease (PD) candidate PRX002 reduced free serum alpha synuclein (SNCA) levels by up to 96% in a Phase I trial (p<0.…

    Published on 3/20/2015
  • CLINICAL NEWS: Sanofi on track to resubmit NDA for lixisenatide

    Sanofi (Euronext:SAN; NYSE:SNY) said it now plans to resubmit an NDA for lixisenatide to FDA in 3Q15 after releasing data showing the compound was non-inferior, but not superior, to placebo for cardiovascular safety in …

    Published on 3/19/2015
  • CLINICAL NEWS: AstraZeneca meets in Phase III COPD trials

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said PT003 met the primary endpoint of the Phase III PINNACLE 1 and PINNACLE 2 studies to treat chronic obstructive pulminary disease (COPD). In both trials, PT003 led to …

    Published on 3/18/2015
  • CLINICAL NEWS: Esperion hits record high on ETC-1002 results

    Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) jumped $22.50 (29%) to $99.60, hitting an all-time high on Tuesday after the company said ETC-1002 met the primary endpoint of lowering LDL-cholesterol vs. placebo in a…

    Published on 3/17/2015
  • CLINICAL NEWS: Sirtex falls on Phase III SIR-Sphere results

    Sirtex Medical Ltd. (ASX:SRX) plummeted A$21.47 (55%) to A$17.53 on Tuesday after SIR-Spheres missed the primary endpoint of significantly improving progression-free survival (PFS) when added to first-line chemotherapy …

    Published on 3/17/2015
  • CLINICAL NEWS: AZ unveils Brilinta data, seeks label extension

    AstraZeneca plc (LSE:AZN; NYSE:AZN) revealed new details from a 21,000-patient CV outcomes study showing that long-term use of the anticoagulant Brilinta ticagrelor reduced the incidence of major thrombotic …

    Published on 3/16/2015
  • CLINICAL NEWS: Imbruvica combo meets Phase III endpoint

    Pharmacyclics Inc. (NASDAQ:PCYC) said Imbruvica ibrutinib plus bendamustine and rituximab met the primary endpoint of improving progression-free survival (PFS) vs. placebo in the Phase III HELIOS trial to treat chronic …

    Published on 3/16/2015
  • CLINICAL NEWS: CTI falls on detailed pacritinib data

    CTI BioPharma Corp. (NASDAQ:CTIC) shed $0.63 (24%) to $1.97 on Friday as investors reviewed detailed Phase III data for pacritinib to treat myelofibrosis (MF) and concluded the results were not as consistent with Phase …

    Published on 3/13/2015
  • CLINICAL NEWS: Neuralstem falls on ALS Phase II

    Neuralstem Inc. (NYSE-M:CUR) fell $1.37 (37%) to $2.37 on Thursday after reporting that its NSI-566 human neural stem cells slowed disease progression in less than half of patients in a Phase II trial to treat …

    Published on 3/12/2015
  • CLINICAL NEWS: Egalet speeds NDA timeline for abuse-deterrent morphine

    Egalet Corp. (NASDAQ:EGLT) rose $1.02 to $14.99 on news that it plans to submit an NDA by YE15 for Egalet-001 for pain management. The company had planned to submit an NDA in mid-2016 for the abuse-deterrent, extended-…

    Published on 3/11/2015
  • CLINICAL NEWS: Ocular's corticosteroid plug meets Phase IIIa endpoints

    Ocular Therapeutix Inc. (NASDAQ:OCUL) said its dexamethasone-loaded punctum plug (OTX-DP) met both primary efficacy endpoints in a Phase IIIa trial to treat pain and inflammation associated with cataract surgery. The …

    Published on 3/10/2015
  • CLINICAL NEWS: CTI's pacritinib meets Phase III endpoint

    CTI BioPharma Corp. (NASDAQ:CTIC) gained $0.16 to $2.81 after reporting pacritinib met the primary endpoint of the Phase III PERSIST-1 trial to treat patients with primary or secondary myelofibrosis (MF).A statistically…

    Published on 3/9/2015
  • CLINICAL NEWS: Zafgen rises on more beloranib data

    Zafgen Inc. (NASDAQ:ZFGN) gained $3.05 to $41.80 on Monday after reporting full results from a Phase II trial in which beloranib led to weight loss in adults with hypothalamic injury associated obesity (HIAO) without …

    Published on 3/9/2015
  • CLINICAL NEWS: Orexigen holds gains on CV outcomes data

    Orexigen Therapeutics Inc. (NASDAQ:OREX) climbed $0.84 (11%) to $8.48 on Wednesday, adding $103.9 million in market cap, as investors overlooked controversy about how interim data were disclosed from the LIGHT …

    Published on 3/4/2015
  • CLINICAL NEWS: Portola reports Phase III antidote data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) rose $2.68 to $40.76 on Monday after reporting full data from the first part of the Phase III ANNEXA-R study, in which anticoagulant antidote andexanet alfa met all primary and…

    Published on 3/2/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993